Beneficial ownership — 13D / 13G
87,281 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Lind Global Fund II LP | WINT Windtree Therapeutics Inc | 13G/A | 5.3% | Dec 31, 2023 | 2y |
| Muhleisen, Dan D. | NNI Nelnet Inc | 13G/A | 14% | Dec 31, 2023 | 2y |
| Mizuho Financial Group, Inc. | TGAA Target Global Acquisition I Corp. Class A Ordinary Share | 13G | 7.94% | Dec 31, 2023 | 2y |
| Lind Global Fund II LP | AUMN Golden Minerals Co | 13G/A | 9.9% | Dec 31, 2023 | 2y |
| Henry R. Kravis | KKR KKR & Co. Inc. | 13G/A | 9.4% | Dec 31, 2023 | 2y |
| KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | FHB First Hawaiian, Inc. | 13G/A | 10.15% | Dec 31, 2023 | 2y |
| GATES FOUNDATION TRUST | CAF Morgan Stanley China A Share Fund, Inc. | 13G/A | 7.6% | Dec 31, 2023 | 2y |
| Heard Capital LLC | ATEX Anterix Inc. | 13G/A | 9.75% | Dec 31, 2023 | 2y |
| Fortune Enterprise Holdings Limited | BDAI Biddance AI Systems, Inc. | 13G | 56.9% | Dec 31, 2023 | 2y |
| Dodge & Cox | OXY Occidental Petroleum Corp | 13G/A | 10.7% | Dec 31, 2023 | 2y |
| Aaron Cowen | AKLI Akili, Inc. Common Stock | 13G/A | 6% | Dec 31, 2023 | 2y |
| JANUS HENDERSON GROUP PLC | SLNO Soleno Therapeutics Inc | 13G/A | 8.3% | Dec 31, 2023 | 2y |
| SUVRETTA CAPITAL MANAGEMENT, LLC | FULC Fulcrum Therapeutics, Inc. | 13G/A | 8.9% | Dec 31, 2023 | 2y |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | GBLI Global Indemnity Group, LLC | 13G/A | 10.39% | Dec 31, 2023 | 2y |
| MMCAP International Inc. SPC | XBP XBP Global Holdings, Inc. | 13G/A | 0% | Dec 31, 2023 | 2y |
| Prosight Management, LP | LBPH Longboard Pharmaceuticals, Inc. Common Stock | 13G/A | 0% | Dec 31, 2023 | 2y |
| Dodge & Cox | LYB LyondellBasell Industries N.V. | 13G/A | 5% | Dec 31, 2023 | 2y |
| SB INVESTMENT ADVISERS (UK) LTD | VIR Vir Biotechnology, Inc. | 13G/A | 12.4% | Dec 31, 2023 | 2y |
| Ned N. Fleming, III | ROAD Construction Partners, Inc. | 13G/A | 13.1% | Dec 31, 2023 | 2y |
| Mizuho Financial Group, Inc. | APXI APx Acquisition Corp. I Class A Ordinary Share | 13G | 5.99% | Dec 31, 2023 | 2y |
| BOOTHBAY FUND MANAGEMENT, LLC | STI Solidion Technology Inc. | 13G/A | 0% | Dec 31, 2023 | 2y |
| Avidity Partners Management LP | CYT Cyteir Therapeutics, Inc. Common Stock | 13G/A | 0% | Dec 31, 2023 | 2y |
| SB INVESTMENT ADVISERS (UK) LTD | COMP Compass, Inc. | 13G/A | 21.2% | Dec 31, 2023 | 2y |
| BlackRock Inc. | XIFR XPLR Infrastructure, LP | 13G/A | 7.7% | Dec 31, 2023 | 2y |
| Polar Asset Management Partners Inc. | JWAC Jupiter Wellness Acquisition Corp. Class A Common Stock | 13G/A | 4.9% | Dec 31, 2023 | 2y |
| Banyan Partners III Ltd. | YSG Yatsen Holding Ltd | 13G/A | 8% | Dec 31, 2023 | 2y |
| Archon Capital Management LLC | APYX Apyx Medical Corp | 13G/A | 9.96% | Dec 31, 2023 | 2y |
| Karpus Management, Inc. | KVACF Keen Vision Acquisition Corp. | 13G | 6.6% | Dec 31, 2023 | 2y |
| Mizuho Financial Group, Inc. | CURR Currenc Group Inc. | 13G | 7.4% | Dec 31, 2023 | 2y |
| SOFTBANK GROUP CORP. | NMRA Neumora Therapeutics, Inc. | 13G | 5% | Dec 31, 2023 | 2y |
| Shlomi Ben Haim | FROG JFrog Ltd | 13G/A | 4.4% | Dec 31, 2023 | 2y |
| Richard A. Miller | CRVS Corvus Pharmaceuticals, Inc. | 13G/A | 7.19% | Dec 31, 2023 | 2y |
| RCP Opp Fund I GP, L.P. | VCTR Victory Capital Holdings, Inc. | 13G/A | 1.87% | Dec 31, 2023 | 2y |
| Hill City Capital, LP | CCLP CSI Compressco LP | 13G/A | 5.25% | Dec 31, 2023 | 2y |
| Focus Impact Sponsor, LLC | DEVSF DevvStream Legacy Corp. | 13G/A | 90.8% | Dec 31, 2023 | 2y |
| TCG Crossover GP I, LLC | CBAY Cymabay Therapeutics | 13G/A | 0% | Dec 31, 2023 | 2y |
| Polar Capital Holdings Plc | CLDX Celldex Therapeutics, Inc. | 13G | 5.73% | Dec 31, 2023 | 2y |
| Champlain Investment Partners, LLC | FRPT Freshpet, Inc. | 13G/A | 7.86% | Dec 31, 2023 | 2y |
| BlackRock Inc. | FTV Fortive Corp | 13G/A | 9% | Dec 31, 2023 | 2y |
| Lind Global Fund II LP | TTOO T2 Biosystems, Inc | 13G/A | 0.5% | Dec 31, 2023 | 2y |
| ALKEON CAPITAL MANAGEMENT LLC | KROS Keros Therapeutics, Inc. | 13G/A | 5% | Dec 31, 2023 | 2y |
| BANK OF AMERICA CORP /DE/ | RVT Royce Small-Cap Trust, Inc. | 13G | 5.1% | Dec 31, 2023 | 2y |
| Stonepine Capital Management, LLC | EOLS Evolus, Inc. | 13G/A | 9.3% | Dec 31, 2023 | 2y |
| JANUS HENDERSON GROUP PLC | CCSI Consensus Cloud Solutions, Inc. | 13G/A | 8.2% | Dec 31, 2023 | 2y |
| Karpus Management, Inc. | MCAF Mountain Crest Acquisition Corp. IV Common Stock | 13G/A | 8.66% | Dec 31, 2023 | 2y |
| Tarang P. Amin | ELF e.l.f. Beauty, Inc. | 13G/A | 3.4% | Dec 31, 2023 | 2y |
| Nicholas T. Curtis | LNSR LENSAR, Inc. | 13G/A | 7.9% | Dec 31, 2023 | 2y |
| Delores B. Weaver | SHOE Shoe Station Group Inc | 13G/A | 32.8% | Dec 31, 2023 | 2y |
| Value Base Ltd. | CGNT Cognyte Software Ltd. | 13G/A | 5.25% | Dec 31, 2023 | 2y |
| Lip-Bu Tan | CRDO Credo Technology Group Holding Ltd | 13G/A | 2.2% | Dec 31, 2023 | 2y |